Goldman is trying to get an entry point on the best stock for 2014. Smarts would be smart to buy now and hold for the year. Too much potential coming to profit in teh next 6-9 months. Guidance will be higher and stock will continue to climb.
DOn't sell, start to buy before earnings.
If you are right, I will add to my position. Either way, earnings will be awesome and I will collect my dividend.
Obamacare has also created a tranch of part time employees now requiring two jobs to make ends meet. Washington policies are failing the middle class in every city you visit.
Liberals always want to do something with other peoples money. Pony up your own and pay your deab beat neighbors premiums, but don't tell me how to spend my cash.
For what its worth, 539 rate QCOR as an outperform with 63 rating it as an under perform. That light the shorts see at the end of the tunnel is an oncomeing train of very strong Acthar growth. Only fictitous yellow journalism can smear this company. Fundys will be forced to buy it up higher when guidance is raised at the next quarterly earnings conference.
Acthar: According to a recent investor presentation, sales of Acthar have grown from $88 million in 2009 to a total of $717 in the last 4 quarters. The chart from the investor presentations shows that even though Acthar has grown extremely fast the last 5 years, there is still potential because Acthar has barely penetrated the market for many of the indications Acthar is approved. With Questcor focusing on building awareness about Acthar with patients, there is potentially MUCH more growth in shares of Questcor.
On Thursday, December 19th analysts at Bank of America raised their price target on Celgene to $196.00 per share. While earlier this month Credit Suisse upgraded the stock from a "neutral" to an "outperform" and raised its price target from $165.00 to $210.00, giving the stock over a 25% upside potential. Citigroup also reiterated a "buy" on the stock with a price target of $204.00, and UBS raised its price target from $163.00 to $200.00. Zacks, however, maintains a "neutral" rating and has a price target of $171.00.
I expect a renewed push towards $180. Afterall, its only a matter of time and probably due this quarter anyway.
Ummmm better check the pipeline coming on and tune into the conference call. If you insist on shorting, you'll be wearing the latest good will fashions by years end.
Sucks to always be wrong. Best ot find another stock to short if he can't change his mind as news releases update teh investment community.
Shorts are in big trouble with this stock starting out the new year. They may see this ratchet passed $75 in a matter of weeks and still pay thei dividends to us longs.
Thx in advance shorties.
Shorts will be in real trouble at earnings call when management continues to share 25% growth rate, reaffirms the dividend, and announces another 250k share buyback.
Ka-Ching Ka-ching ka-ching. QCOR is going drastically higher.
BTW Shorts, thanks in advance for the dividend payment you will soon be sending me:-)
Always a short squeeze prior to earnings release, but this looks like a gusher.
Hang on longs. QCOR belongs at $100 and has a P/E of 12 right now. Unfathomable.
The Company also announced today that it made open market purchases during the fourth quarter of 2013 of approximately 500,000 shares of Questcor common stock through December 10, 2013. The shares were purchased at an average price of $57.21 per share.